サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：腸閉塞治療市場レポート：2030年までの動向、予測、競合分析
市場調査レポート
商品コード
1356894

腸閉塞治療市場レポート：2030年までの動向、予測、競合分析

Intestinal Pseudo Obstruction Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日: | 発行: Lucintel | ページ情報: 英文 150 Pages | 納期: 3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円

ご注意:　DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

腸閉塞治療市場レポート：2030年までの動向、予測、競合分析
出版日: 2023年09月01日
発行: Lucintel
ページ情報: 英文 150 Pages
納期: 3営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

腸管偽閉塞治療の動向と予測

世界の腸管偽閉塞治療市場は、2024年から2030年までのCAGRが5.1％で、2030年までに推定214億米ドルに達すると予測されます。この市場の主な促進要因は、消化管疾患の有病率の増加、ヘルスケアプロバイダーや患者の意識の高まり、特定の治療法に関する医薬品の技術革新の進展です。世界の腸管偽閉塞治療市場の将来は、病院・診療所市場と外来ケアセンター市場にビジネスチャンスがあり、有望視されています。

腸閉塞治療市場の洞察

  • Lucintelは、予測期間中、薬物療法が最大のセグメントであり続けると予測しています。
  • 病院は、特に重症例や合併症の管理において、腸閉塞の治療において重要な役割を果たすため、最大セグメントであり続けるでしょう。
  • 北米は、疾患に対する意識の高まり、主要プレイヤーの存在、同地域のヘルスケア産業の拡大により、予測期間中も最大セグメントであり続けると思われます。

本レポートでは、以下の11の主要な質問に回答しています：

  • Q.1.市場セグメントのうち、最も有望かつ高成長な機会は何か？
  • Q.2.どのセグメントがより速いペースで成長するのか、またその理由は？
  • Q.3.今後成長が加速すると思われる地域とその理由は？
  • Q.4.市場力学に影響を与える主な要因は何か？市場における主な課題とビジネスリスクは？
  • Q.5.この市場におけるビジネスリスクと競合の脅威は？
  • Q.6.この市場における新たな動向とその理由は？
  • Q.7.市場における顧客の需要の変化にはどのようなものがありますか？
  • Q.8.この市場における新たな開発と、その開発をリードしている企業は？
  • Q.9.この市場における主要企業は？主要企業は事業成長のためにどのような戦略的取り組みを進めているのか？
  • Q.10.この市場における競合製品にはどのようなものがあり、材料や製品の代替による市場シェア低下の脅威はどの程度ありますか？
  • Q.11.過去5年間にどのようなM&Aが行われ、業界にどのような影響を与えましたか？

目次

第1章 エグゼクティブサマリー

第2章 世界の仮性腸閉塞治療市場：市場力学

  • イントロダクション、背景、分類
  • サプライチェーン
  • 業界の促進要因と課題

第3章 2018年から2030年までの市場動向と予測分析

  • マクロ経済動向（2018～2023年）と予測（2024～2030年）
  • 世界の仮性腸閉塞治療市場の動向（2018～2023年）と予測（2024～2030年）
  • 症状別の世界の仮性腸閉塞治療市場
    • 急性
    • 慢性
  • 診断別の世界の仮性腸閉塞治療市場
    • 身体検査
    • 生検
    • 血液検査
    • 胃内容排出検査
    • 画像検査
    • その他
  • 治療別の世界の仮性腸閉塞治療市場
    • 薬
    • 手術
    • ダイエット
    • その他
  • 最終用途別の世界の偽腸閉塞治療市場
    • 病院とクリニック
    • 外来診療センター
    • その他

第4章 2018年から2030年までの地域別の市場動向と予測分析

  • 地域別の世界の仮性腸閉塞治療市場
  • 北米の仮性腸閉塞治療市場
  • 欧州の仮性腸閉塞治療市場
  • アジア太平洋の偽腸閉塞治療市場
  • その他地域腸管仮性閉塞治療市場

第5章 競合の分析

  • 製品ポートフォリオ分析
  • 運用上の統合
  • ポーターのファイブフォース分析

第6章 成長機会と戦略的分析

  • 成長機会分析
    • 症状別の世界の仮性腸閉塞治療市場の成長機会
    • 診断別の世界の仮性腸閉塞治療市場の成長機会
    • 治療別の世界の仮性腸閉塞治療市場の成長機会
    • 最終用途別の世界の仮性腸閉塞治療市場の成長機会
    • 地域別の世界の仮性腸閉塞治療市場の成長機会
  • 世界の仮性腸閉塞治療市場の新たな動向
  • 戦略的分析
    • 新製品の開発
    • 世界の仮性腸閉塞治療市場の能力拡大
    • 世界の仮性腸閉塞治療市場における合併、買収、合弁事業
    • 認証とライセンシング

第7章 有力企業の企業プロファイル

  • Pfizer
  • Cipla
  • GlaxoSmithKline
  • Teva Pharmaceutical
  • Eli Lilly
  • Novartis
  • Johnson & Johnson
  • Dr. Reddy's Laboratories
  • F. Hoffmann-La Roche
  • Lupin Limited
目次

Intestinal Pseudo Obstruction Treatment Trends and Forecast

The future of the global intestinal pseudo obstruction treatment market looks promising with opportunities in the hospitals & clinic and ambulatory care center markets. The global intestinal pseudo obstruction treatment market is expected to reach an estimated $21.40 billion by 2030 with a CAGR of 5.1% from 2024 to 2030. The major drivers for this market are increasing prevalence of gastrointestinal cases, rising awareness among healthcare providers and patients, and growing pharmaceutical innovations for specific treatments.

A more than 150-page report is developed to help in your business decisions.

Intestinal Pseudo Obstruction Treatment by Segment

The study includes a forecast for the global intestinal pseudo obstruction treatment by condition, diagnosis, treatment, end use, and region.

Intestinal Pseudo Obstruction Treatment Market by Condition [Shipment Analysis by Value from 2018 to 2030]:

  • Acute
  • Chronic

Intestinal Pseudo Obstruction Treatment Market by Diagnosis [Shipment Analysis by Value from 2018 to 2030]:

  • Physical Examination
  • Biopsy
  • Blood Test
  • Gastric Emptying Tests
  • Imaging Tests
  • Others

Intestinal Pseudo Obstruction Treatment Market by Treatment [Shipment Analysis by Value from 2018 to 2030]:

  • Medication
  • Surgery
  • Diet
  • Others

Intestinal Pseudo Obstruction Treatment Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Others

Intestinal Pseudo Obstruction Treatment Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Intestinal Pseudo Obstruction Treatment Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies intestinal pseudo obstruction treatment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the intestinal pseudo obstruction treatment companies profiled in this report include-

  • Pfizer
  • Cipla
  • Glaxosmithkline
  • Teva Pharmaceutical
  • Eli Lilly
  • Novartis
  • Johnson & Johnson
  • Dr. Reddy'S Laboratories
  • F. Hoffmann-La Roche
  • Lupin Limited

Intestinal Pseudo Obstruction Treatment Market Insights

  • Lucintel forecasts that medication will remain the largest segment over the forecast period.
  • Hospitals will remain the largest segment due to as hospital playa an important role in the treatment of intestinal pseudo-obstruction, especially in managing severe cases and complications.
  • North America will remain the largest segment over the forecast period due to increasing awareness towards diseases, presence of major players, and expanding healthcare industry in the region.

Features of the Global Intestinal Pseudo Obstruction Treatment Market

  • Market Size Estimates: Intestinal pseudo obstruction teatment market size estimation in terms of value ($B).
  • Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
  • Segmentation Analysis: Intestinal pseudo obstruction teatment market by various segments, such as by condition, diagnosis, treatment, end use and region in terms of($B).
  • Regional Analysis: Intestinal pseudo obstruction teatment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different conditions, diagnosis, treatment, end uses, and region.s for the intestinal pseudo obstruction treatment market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the intestinal pseudo obstruction treatment market.
  • Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1. What is the intestinal pseudo obstruction treatment market size?

Answer: The global intestinal pseudo obstruction treatment market is expected to reach an estimated $21.40 billion by 2030.

Q.2. What is the growth forecast for intestinal pseudo obstruction treatment market?

Answer: The global intestinal pseudo obstruction treatment market is expected to grow with a CAGR of 5.1% from 2024 to 2030.

Q.3. What are the major drivers influencing the growth of the intestinal pseudo obstruction treatment market?

Answer: The major drivers for this market are increasing prevalence of gastrointestinal cases, rising awareness among healthcare providers and patients, and growing pharmaceutical innovations for specific treatments.

Q.4. What are the major segments for intestinal pseudo obstruction treatment market?

Answer: The future of the intestinal pseudo obstruction treatment market looks promising with opportunities in the hospitals & clinic and ambulatory care center markets.

Q.5. Who are the key intestinal pseudo obstruction treatment market companies?

Answer: Some of the key intestinal pseudo obstruction treatment companies are as follows:

  • Pfizer
  • Cipla
  • GlaxoSmithKline
  • Teva Pharmaceutical
  • Eli Lilly
  • Novartis
  • Johnson & Johnson
  • Dr. Reddy's Laboratories
  • F. Hoffmann-La Roche
  • Lupin Limited

Q.6. Which intestinal pseudo obstruction treatment market segment will be the largest in future?

Answer: Lucintel forecasts that medication will remain the largest segment over the forecast period.

Q.7. In intestinal pseudo obstruction treatment market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest segment over the forecast period due to increasing awareness towards diseases, presence of major players, and expanding healthcare industry in the region.

Q.8. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the intestinal pseudo obstruction treatment market by condition (acute and chronic), diagnosis (physical examination, biopsy, blood test, gastric emptying tests, imaging tests, and others), treatment (medication, surgery, diet, and others), end use (hospitals & clinics, ambulatory care centers, and others), and region. (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Intestinal Pseudo Obstruction Treatment Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Intestinal Pseudo Obstruction Treatment Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Intestinal Pseudo Obstruction Treatment Market by Condition
    • 3.3.1: Acute
    • 3.3.2: Chronic
  • 3.4: Global Intestinal Pseudo Obstruction Treatment Market by Diagnosis
    • 3.4.1: Physical Examination
    • 3.4.2: Biopsy
    • 3.4.3: Blood Test
    • 3.4.4: Gastric Emptying Tests
    • 3.4.5: Imaging Tests
    • 3.4.6: Others
  • 3.5: Global Intestinal Pseudo Obstruction Treatment Market by Treatment
    • 3.5.1: Medication
    • 3.5.2: Surgery
    • 3.5.3: Diet
    • 3.5.4: Others
  • 3.6: Global Intestinal Pseudo Obstruction Treatment Market by End Use
    • 3.6.1: Hospitals & Clinics
    • 3.6.2: Ambulatory Care Centers
    • 3.6.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Intestinal Pseudo Obstruction Treatment Market by Region
  • 4.2: North American Intestinal Pseudo Obstruction Treatment Market
    • 4.2.2: North American Intestinal Pseudo Obstruction Treatment Market by End Use: Hospitals & Clinics, Ambulatory Care Centers, and Others
  • 4.3: European Intestinal Pseudo Obstruction Treatment Market
    • 4.3.1: European Intestinal Pseudo Obstruction Treatment Market by Treatment: Medication, Surgery, Diet, and Others
    • 4.3.2: European Intestinal Pseudo Obstruction Treatment Market by End Use: Hospitals & Clinics, Ambulatory Care Centers, and Others
  • 4.4: APAC Intestinal Pseudo Obstruction Treatment Market
    • 4.4.1: APAC Intestinal Pseudo Obstruction Treatment Market by Treatment: Medication, Surgery, Diet, and Others
    • 4.4.2: APAC Intestinal Pseudo Obstruction Treatment Market by End Use: Hospitals & Clinics, Ambulatory Care Centers, and Others
  • 4.5: ROW Intestinal Pseudo Obstruction Treatment Market
    • 4.5.1: ROW Intestinal Pseudo Obstruction Treatment Market by Treatment: Medication, Surgery, Diet, and Others
    • 4.5.2: ROW Intestinal Pseudo Obstruction Treatment Market by End Use: Hospitals & Clinics, Ambulatory Care Centers, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Intestinal Pseudo Obstruction Treatment Market by Condition
    • 6.1.2: Growth Opportunities for the Global Intestinal Pseudo Obstruction Treatment Market by Diagnosis
    • 6.1.3: Growth Opportunities for the Global Intestinal Pseudo Obstruction Treatment Market by Treatment
    • 6.1.4: Growth Opportunities for the Global Intestinal Pseudo Obstruction Treatment Market by End Use
    • 6.1.5: Growth Opportunities for the Global Intestinal Pseudo Obstruction Treatment Market by Region
  • 6.2: Emerging Trends in the Global Intestinal Pseudo Obstruction Treatment Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Intestinal Pseudo Obstruction Treatment Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Intestinal Pseudo Obstruction Treatment Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Pfizer
  • 7.2: Cipla
  • 7.3: GlaxoSmithKline
  • 7.4: Teva Pharmaceutical
  • 7.5: Eli Lilly
  • 7.6: Novartis
  • 7.7: Johnson & Johnson
  • 7.8: Dr. Reddy's Laboratories
  • 7.9: F. Hoffmann-La Roche
  • 7.10: Lupin Limited